Drug Profile
Belagenpumatucel-L
Alternative Names: Glionix; Lucanix; Ranagengliotucel-T; TGF-beta2 antisense gene modified allogeneic tumour cell vaccine - NovaRxLatest Information Update: 19 Aug 2016
Price :
$50
*
At a glance
- Originator Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Developer NovaRx Corporation
- Class Antisense DNA; Cancer vaccines; DNA vaccines; Tumour cell vaccines
- Mechanism of Action Immunostimulants; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioma; Non-small cell lung cancer
Most Recent Events
- 19 Aug 2016 NovaRx intends to initiate new clinical studies for Belagenpumatucel-L, either as monotherapy or combination therapy
- 28 Sep 2013 Efficacy data from a phase III trial in Non-small cell lung cancer presented at the European Cancer Congress 2013 (ECC-2013)
- 25 Jul 2013 Discontinued - Phase-I for Glioma in USA (SC) prior to July 2013